Abstract:Background & aims: Chronic hepatitis delta is the most severe form of chronic viral hepatitis and is associated with faster progression towards cirrhosis, liver decompensation, and hepatocellular carcinoma. Hepatitis delta virus (HDV)'s tight dependency on hepatitis B virus and the host cell machinery for its life cycle limits the development of direct-acting antivirals. Thus, we aimed to identify compounds that could block HDV replication by targeting its antigenomic ribozyme. Methods: We generated stable Huh7 human hepatoma cells expressing a reporter gene (Gaussia luciferase) either downstream (Gluc-2xRz) or upstream (2xRz-Gluc) of two HDV antigenomic ribozyme sequences. We performed high-throughput screening of three small molecule libraries. The secreted luciferase was measured as a readout of ribozyme inhibition upon addition of the molecules. Each plate was considered valid when the Z factor was >0.4. Specificity and toxicity evaluations were performed for the hits with a Z-score >5 and half-maximal inhibitory concentration was calculated by performing a dose-response experiment. Results: A dose-dependent induction of luciferase expression was detected in Gluc-2xRz-transfected cells incubated with the antisense morpholino, suggesting that the catalytic activity of the ribozyme cloned downstream of the reporter gene was efficiently inhibited. Among the 6,644 compounds screened, we identified four compounds that showed a specific inhibitory effect on the HDV antigenomic ribozyme in Gluc-2xRz cells, i.e. three histone deacetylase inhibitors and the purine analogue 8-azaguanine. The latter also significantly decreased HDV replication (by 40%) in differentiated HepaRG cells six days post infection. Conclusion: Using a novel cell culture model, we identified four small molecules active against the antigenomic HDV ribozyme. These results may provide insights into the structural requirements of molecules designed for the potent and specific inhibition of HDV replication. Impact and implications: Chronic hepatitis delta is the most severe form of chronic viral hepatitis and is associated with faster progression towards cirrhosis, liver decompensation, and the development of hepatocellular carcinoma. Despite the current development of several new compounds, there is still a need for efficient antiviral treatments specifically targeting hepatitis delta virus (HDV). This work describes a novel cell culture model that allows for the high-throughput screening of compounds able to inhibit HDV ribozymes. We identified four small molecules active against the antigenomic HDV ribozyme (the ribozyme involved in the early step of HDV replication), with the strongest activity shown by 8-azaguanine, a purine analogue. Our data may provide insights into the structural requirements of molecules designed to inhibit HDV.

Theoretical Examination Of Two Opposite Mechanisms Proposed For Hepatitis Delta Virus Ribozyme

Transition State Features in the Hepatitis Delta Virus Ribozyme Reaction Revealed by Atomic Perturbations.

Dissociative Transition State in Hepatitis Delta Virus Ribozyme Catalysis

Investigation on Activities of Hammerhead Ribozyme Embedded in Genomic RNA of Hepatitis Delta Virus

Computer Analysis of the Cleavage Reaction of Hammerhead Ribozyme.

Efficient Inhibition of Hepatitis B Virus Replication by Hammerhead Ribozymes Delivered by Hepatitis Delta Virus.

Mechanism of Flexibility Control for ATP Access of Hepatitis C Virus NS3 Helicase.

In vitro self-cleavage activity of hepatitis delta virus ribozymes with different length and its significance

Design and activity assessment of HDV ribozymes to trans-cleave HCV RNA

Computational biology approach to uncover hepatitis C virus helicase operation

Evidence That Nucleophile Deprotonation Exceeds Bond Formation in the HDV Ribozyme Transition State.

Hydrophobic and charged residues in the C-terminal arm of hepatitis C virus RNA-dependent RNA polymerase regulate initiation and elongation

The Structural and Mechanistic Origins of Catalysis in Nucleolytic Ribozymes

Identification of selective hepatitis delta virus ribozyme inhibitors by high-throughput screening of small molecule libraries

Combined 3D‐QSAR, Molecular Docking, Molecular Dynamics Simulation, and Binding Free Energy Calculation Studies on the 5‐hydroxy‐2h‐pyridazin‐3‐one Derivatives As HCV NS5B Polymerase Inhibitors

Post-translational Modification of Delta Antigen of Hepatitis D Virus

Evidence for the Role of Active Site Residues in the Hairpin Ribozyme from Molecular Simulations along the Reaction Path

Mutational Analysis of the Structure and Functions of Hepatitis C Virus RNA–dependent RNA Polymerase

Computational Study on the Inhibitor Binding Mode and Allosteric Regulation Mechanism in Hepatitis C Virus Ns3/4a Protein

Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598

Activity of Hdv Ribozymes to Trans-Cleave Hcv Rna